Kishan Mehta - Net Worth and Insider Trading
Kishan Mehta Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Kishan Mehta owns 8 companies in total, including Biohaven Pharmaceutical Holding Co Ltd (BHVN) , Social Capital Suvretta Holdings Corp I (DNAA) , and Social Capital Suvretta Holdings Corp III (DNAC) among others .
Click here to see the complete history of Kishan Mehta’s form 4 insider trades.
Insider Ownership Summary of Kishan Mehta
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
BHVN | Biohaven Pharmaceutical Holding Co Ltd | 2021-06-15 | director |
DNAA | Social Capital Suvretta Holdings Corp I | 2021-06-29 | other: Manager |
DNAC | Social Capital Suvretta Holdings Corp III | 2021-06-29 | other: Manager |
DNAB | Social Capital Suvretta Holdings Corp II | 2021-06-29 | other: Manager |
DNAD | Social Capital Suvretta Holdings Corp IV | 2021-06-29 | other: Manager |
AKLI | Akili Inc | 2021-06-29 | other: Manager |
PROK | ProKidney Corp | 2021-06-29 | other: Manager |
BHVN | Biohaven Ltd | 2022-10-03 | director |
Kishan Mehta Trading Performance
Kishan Mehta Ownership Network
Ownership Network List of Kishan Mehta
Ownership Network Relation of Kishan Mehta
Kishan Mehta Owned Company Details

What does Biohaven Pharmaceutical Holding Co Ltd do?
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.
Who are the key executives at Biohaven Pharmaceutical Holding Co Ltd?
Kishan Mehta is the director of Biohaven Pharmaceutical Holding Co Ltd. Other key executives at Biohaven Pharmaceutical Holding Co Ltd include Officer Matthew Buten , VP & Chief Accounting Officer George C. Clark , and Chief Medical Officer Elyse Stock .
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Trades Summary
Over the past 18 months, Kishan Mehta made no insider transaction in Biohaven Pharmaceutical Holding Co Ltd (BHVN). Other recent insider transactions involving Biohaven Pharmaceutical Holding Co Ltd (BHVN) include a net sale of 15,490 shares made by George C. Clark , a net sale of 62,265 shares made by Declan Doogan , and a net purchase of 38,000 shares made by Gregory Bailey .
In summary, during the past 3 months, insiders sold 0 shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 153,613 shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) were sold and 43,000 shares were bought by its insiders, resulting in a net sale of 110,613 shares.
Biohaven Pharmaceutical Holding Co Ltd (BHVN)'s detailed insider trading history can be found in Insider Trading Tracker table.
NYSE:BHVN Insider Transactions
- 1
Insider | Position | Date | Buy/Sell | Shares | Shares Owned | Trade Price($) | Trade Percentage(%) | Cost($1000) | Price change since trade(%) | Share ownership details | Filing Date |
---|
- 1

What does Social Capital Suvretta Holdings Corp I do?
Social Capital Suvretta Holdings Corp I is a blank check company.
Who are the key executives at Social Capital Suvretta Holdings Corp I?
Kishan Mehta is the other: Manager of Social Capital Suvretta Holdings Corp I. Other key executives at Social Capital Suvretta Holdings Corp I include Chief Financial Officer James Ryans , other: Manager Chamath Palihapitiya , and director & 10 percent owner Scs Sponsor I Llc .
Social Capital Suvretta Holdings Corp I (DNAA) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Social Capital Suvretta Holdings Corp I (DNAA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Social Capital Suvretta Holdings Corp I (DNAA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Social Capital Suvretta Holdings Corp I (DNAA)'s detailed insider trading history can be found in Insider Trading Tracker table.
NAS:DNAA Insider Transactions
- 1
Insider | Position | Date | Buy/Sell | Shares | Shares Owned | Trade Price($) | Trade Percentage(%) | Cost($1000) | Price change since trade(%) | Share ownership details | Filing Date |
---|
- 1

What does Social Capital Suvretta Holdings Corp III do?
Social Capital Suvretta Holdings Corp III is a blank check company.
Who are the key executives at Social Capital Suvretta Holdings Corp III?
Kishan Mehta is the other: Manager of Social Capital Suvretta Holdings Corp III. Other key executives at Social Capital Suvretta Holdings Corp III include 10 percent owner Control Empresarial De Capitales S.a. De C.v. , 10 percent owner Sc Pipe Holdings Llc , and 10 percent owner Tolerantia, Llc .
Social Capital Suvretta Holdings Corp III (DNAC) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Social Capital Suvretta Holdings Corp III (DNAC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Social Capital Suvretta Holdings Corp III (DNAC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Social Capital Suvretta Holdings Corp III (DNAC)'s detailed insider trading history can be found in Insider Trading Tracker table.
NAS:DNAC Insider Transactions
- 1
Insider | Position | Date | Buy/Sell | Shares | Shares Owned | Trade Price($) | Trade Percentage(%) | Cost($1000) | Price change since trade(%) | Share ownership details | Filing Date |
---|
- 1

What does Social Capital Suvretta Holdings Corp II do?
Social Capital Suvretta Holdings Corp II is a blank check company.
Who are the key executives at Social Capital Suvretta Holdings Corp II?
Kishan Mehta is the other: Manager of Social Capital Suvretta Holdings Corp II. Other key executives at Social Capital Suvretta Holdings Corp II include Chief Financial Officer James Ryans , other: Manager Chamath Palihapitiya , and Director of Research Shoney Katz .
Social Capital Suvretta Holdings Corp II (DNAB) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Social Capital Suvretta Holdings Corp II (DNAB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Social Capital Suvretta Holdings Corp II (DNAB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Social Capital Suvretta Holdings Corp II (DNAB)'s detailed insider trading history can be found in Insider Trading Tracker table.
NAS:DNAB Insider Transactions
- 1
Insider | Position | Date | Buy/Sell | Shares | Shares Owned | Trade Price($) | Trade Percentage(%) | Cost($1000) | Price change since trade(%) | Share ownership details | Filing Date |
---|
- 1

What does Social Capital Suvretta Holdings Corp IV do?
Social Capital Suvretta Holdings Corp IV is a newly incorporated blank check company.
Who are the key executives at Social Capital Suvretta Holdings Corp IV?
Kishan Mehta is the other: Manager of Social Capital Suvretta Holdings Corp IV. Other key executives at Social Capital Suvretta Holdings Corp IV include Chief Financial Officer James Ryans , other: Manager Chamath Palihapitiya , and Director of Research Shoney Katz .
Social Capital Suvretta Holdings Corp IV (DNAD) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Social Capital Suvretta Holdings Corp IV (DNAD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Social Capital Suvretta Holdings Corp IV (DNAD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Social Capital Suvretta Holdings Corp IV (DNAD)'s detailed insider trading history can be found in Insider Trading Tracker table.
NAS:DNAD Insider Transactions
- 1
Insider | Position | Date | Buy/Sell | Shares | Shares Owned | Trade Price($) | Trade Percentage(%) | Cost($1000) | Price change since trade(%) | Share ownership details | Filing Date |
---|
- 1

What does Akili Inc do?
Akili Inc is a digital medicine company pioneering the development of cognitive treatments through game-changing technologies.
Who are the key executives at Akili Inc?
Kishan Mehta is the other: Manager of Akili Inc. Other key executives at Akili Inc include director & 10 percent owner Chamath Palihapitiya , Chief Legal Officer Jacqueline Studer , and See Remarks Matthew Franklin .
Akili Inc (AKLI) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Akili Inc (AKLI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Akili Inc (AKLI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Akili Inc (AKLI)'s detailed insider trading history can be found in Insider Trading Tracker table.
NAS:AKLI Insider Transactions
- 1
Insider | Position | Date | Buy/Sell | Shares | Shares Owned | Trade Price($) | Trade Percentage(%) | Cost($1000) | Price change since trade(%) | Share ownership details | Filing Date |
---|
- 1

What does ProKidney Corp do?
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease.
Who are the key executives at ProKidney Corp?
Kishan Mehta is the other: Manager of ProKidney Corp. Other key executives at ProKidney Corp include Chief People Officer Mary Weger , 10 percent owner Control Empresarial De Capitales S.a. De C.v. , and 10 percent owner Sc Pipe Holdings Llc .
ProKidney Corp (PROK) Insider Trades Summary
Over the past 18 months, Kishan Mehta made no insider transaction in ProKidney Corp (PROK). Other recent insider transactions involving ProKidney Corp (PROK) include a net purchase of 10,875 shares made by Aaron Cowen ,
In summary, during the past 3 months, insiders sold 0 shares of ProKidney Corp (PROK) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ProKidney Corp (PROK) were sold and 10,875 shares were bought by its insiders, resulting in a net purchase of 10,875 shares.
ProKidney Corp (PROK)'s detailed insider trading history can be found in Insider Trading Tracker table.
NAS:PROK Insider Transactions
- 1
Insider | Position | Date | Buy/Sell | Shares | Shares Owned | Trade Price($) | Trade Percentage(%) | Cost($1000) | Price change since trade(%) | Share ownership details | Filing Date |
---|
- 1

What does Biohaven Ltd do?
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, immunology, and disease-related biology, including rare disorders. Its neuroscience portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7, glutamate receptors, myostatin, and TRP channels. Its products target diseases such as migraine, depression, bipolar, and schizophrenia.
Who are the key executives at Biohaven Ltd?
Kishan Mehta is the director of Biohaven Ltd. Other key executives at Biohaven Ltd include VP & Chief Accounting Officer George C. Clark , SVP & Clinical Operations Kimberly Gentile , and director & Chief Executive Officer Vlad Coric .
Biohaven Ltd (BHVN) Insider Trades Summary
Over the past 18 months, Kishan Mehta made no insider transaction in Biohaven Ltd (BHVN). Other recent insider transactions involving Biohaven Ltd (BHVN) include a net purchase of 1,021,110 shares made by Vlad Coric , a net purchase of 3,900,000 shares made by John W Childs , and a net purchase of 200,000 shares made by Gregory Bailey .
In summary, during the past 3 months, insiders sold 0 shares of Biohaven Ltd (BHVN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Biohaven Ltd (BHVN) were sold and 5,273,490 shares were bought by its insiders, resulting in a net purchase of 5,273,490 shares.
Biohaven Ltd (BHVN)'s detailed insider trading history can be found in Insider Trading Tracker table.
NYSE:BHVN Insider Transactions
- 1
Insider | Position | Date | Buy/Sell | Shares | Shares Owned | Trade Price($) | Trade Percentage(%) | Cost($1000) | Price change since trade(%) | Share ownership details | Filing Date |
---|
- 1
Kishan Mehta Mailing Address
Above is the net worth, insider trading, and ownership report for Kishan Mehta. You might contact Kishan Mehta via mailing address: 540 West 49th Street, Unit# Ph1n, New York Ny 10019.